U.S. Markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • EUR/USD

    1.1648
    +0.0018 (+0.1514%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3759
    -0.0036 (-0.2628%)
     
  • USD/JPY

    113.4600
    -0.5280 (-0.4632%)
     
  • BTC-USD

    60,616.10
    -1,886.36 (-3.02%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

LAWSUITS FILED AGAINST SRNE, CLNY and MYL - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / July 1, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Sorrento Therapeutics, Inc. (SRNE)

CONTACT JAKUBOWITZ ABOUT SRNE:
https://claimyourloss.com/securities/sorrento-therapeutics-inc-loss-submission-form/?id=7707&from=1

Class Period: May 15, 2020 - May 22, 2020

Lead Plaintiff Deadline: July 27, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Colony Capital, Inc. (CLNY)

CONTACT JAKUBOWITZ ABOUT CLNY:
https://claimyourloss.com/securities/colony-capital-inc-loss-submission-form/?id=7707&from=1

Class Period: August 9, 2019 - May 7, 2020

Lead Plaintiff Deadline: July 27, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Colony's sale of its industrial real estate portfolio and the bifurcation of Colony Credit Real Estate's portfolio were foreseeably likely to negatively impact Colony's financial and operating results; (ii) certain of Colony's remaining portfolio companies carried unsustainable levels of debt secured by hotels and healthcare-related properties and were thus at a significant risk of default; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Mylan N.V. (MYL)

CONTACT JAKUBOWITZ ABOUT MYL:
https://claimyourloss.com/securities/mylan-n-v-loss-submission-form/?id=7707&from=1

Class Period: February 16, 2016 - May 7, 2019

Lead Plaintiff Deadline: August 25, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Food and Drug Administration's investigation into the Company's manufacturing plant in Morgantown, West Virginia was the result of whistleblower allegations, and not, as Mylan insinuated, the result of a "regular" inspection; and 2) defendants knew or were reckless in not knowing that, as a result of Mylan's continued efforts to remain uncooperative with the Food and Drug Administration, the Morgantown plant would continue to incur substantial setbacks.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/596009/LAWSUITS-FILED-AGAINST-SRNE-CLNY-and-MYL--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS